ATLANTA CRANIAS: Open Payments
NPI 1720656531 · ORANGE CITY, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,410 in 159 payments from 44 companies in 2025. Trend: 2023 $3,186 · 2024 $4,117 · 2025 $4,410
Food & beverage: $3,162Long term medical supply or device loan: $1,000Education: $248
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 24 | $1,222 |
| ABBVIE INC. | 9 | $252 |
| AstraZeneca Pharmaceuticals LP | 8 | $221 |
| Merck Sharp & Dohme LLC | 8 | $185 |
| PFIZER INC. | 8 | $174 |
| Janssen Biotech, Inc. | 10 | $170 |
| Incyte Corporation | 5 | $160 |
| Eisai Inc. | 6 | $122 |
| GlaxoSmithKline, LLC. | 4 | $106 |
| Astellas Pharma US Inc | 5 | $106 |
Products named: KISQALI, IMFINZI, KEYTRUDA, RYBREVANT, Lenvima, BRUKINSA, Vyloy, PROVENGE.
Industry payments across FL — which companies pay providers there.
